TORONTO, July 24, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) (“Profound” or the “Company”), a commercial-stage medical device company that develops and markets innovative ...

At 24 months' follow-up, the only phase 3 randomized clinical trial to directly compare functional and oncologic outcomes between robot-assisted laparoscopic prostatectomy and open radical retropubic ...

– First multicenter, randomized controlled trial directly comparing a new technology to robotic RP for men with localized prostate cancer to successfully recruit to target enrollment – – TULSA ...

MRI-guided transurethral ultrasound ablation (TULSA) resulted in significantly faster recovery, less perioperative morbidity, and better early functional outcomes than robotic radical prostatectomy in ...

Apa-RP: Multicenter phase 2 study of apalutamide (Apa) and androgen deprivation therapy (ADT) for the treatment of high-risk localized prostate cancer (HR LPC) following radical prostatectomy ...

3D augmented reality-assisted imaging during RARP enabled precise identification and removal of tumor lesions at the level of preserved neurovascular bundles, which may reduce positive surgical ...

The probability of surgical success with telesurgery for radical prostatectomy and partial nephrectomy for small renal masses was non-inferior to local robotic surgery in a small randomized trial. The ...

TORONTO, July 24, 2026 (GLOBE NEWSWIRE) -- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets innovative ...